Aluminium,Tin & Metal Containers #6995802

Brentuximab is used to treat certain types of cancers (Hodgkins lymphoma, systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides). It works by slowing or stopping the growth of cancer cells.

What Adcetris is and what it is used forAdcetris contains the active substancebrentuximab vedotin, an anti-cancer agent, which is made up of a monoclonal antibody linked to a substance intended to kill cancer cells. This substance is delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is a protein which recognises certain cancer cells.Adcetris is used to treat classical Hodgkin lymphoma that has:come back after or not responded to an infusion of your own healthy stem cells into your body (autologous stem cell transplant), orcome back after or never responded to at least two previous therapies, and where you cannot receive additional combination anti-cancer treatments or have an autologous stem cell transplant.Classical Hodgkin lymphoma expresses specific proteins on the cell surface that are different from non-classical Hodgkin lymphoma.Adcetris is also used to lower the likelihood of classical Hodgkin Lymphoma coming back after an autologous stem cell transplant in patients with certain risk factors.Adcetris is used to treat systemic anaplastic large cell lymphoma which is found in your lymph nodes and/or throughout other parts of your body that has:not responded to other types of anti-cancer treatments, orcome back after previous anti-cancer treatment.Hodgkin lymphoma and systemic anaplastic large cell lymphoma are both types of cancer of the white blood cells.Adcetris is used to treat cutaneous T-cell lymphoma (CTCL) in patients who have previously received at least one medicine that travels through the bloodstream.CTCL is a cancer of a certain type of white blood cell called a T-cell that mainly affects the skin. Adcetris is used to treat CTCL where a specific type of protein is present on the cells surface.

kadcyla Small glass container is used for Her2-positive deadly breast cancer, Her2-positive, Deadly breast cancer and other conditions. Kadcyla Small glass container may also be used for purposes not listed in this medicine guide. Kadcyla Small glass container contains Ado-Trastuzumab Emtansine as an active ingredient. Kadcyla Small glass container works by stoping the HER2 receptor signaling . Ado-trastuzumab emtansine is utilized alone to treat specific kinds of bosom malignant growth. This drug is utilized to treat tumors that deliver more than the typical measure of a specific substance called HER2 protein.This prescription is known as a monoclonal neutralizer and microtubule inhibitor conjugate. Ado-trastuzumab emtansine works by connecting to the HER2 malignant growth cells and blocking them from partitioning and developing. It might likewise pulverize the malignant growth cells or flag the body (insusceptible framework) to wreck the disease cells.

Uses:

• KadcylaSmall glass containerisusedforthetreatment, control, prevention, &improvementofthefollowingsicknesses, conditionsandsigns of sickness:- Her2-positive, deadlybreastcancer .

Perjeta 420mg Injection is used to treat breast cancer. It belongs to group of medicine called monoclonal antibodies.

Perjeta 420mg Injection is given as an injection into veins under the supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to

backed by rich industry experiences, we are leading exporter, distributor, supplier & trading company of soliris -eculizumab 300mg in pune, maharashtra, india.

1.1paroxysmal nocturnal hemoglobinuria (pnh)

1.2 atypical hemolytic uremic syndrome (ahus)

1.3 generalized myasthenia gravis (gmg)

soliris is aa complement inhibitor indicated for:

a c the treatment of patients with paroxysmal nocturnal hemoglobinuria (pnh) to reduce hemolysis (1.1).

a c the treatment of patients with atypical hemolytic uremic syndrome (ahus) to inhibit complement-mediated thrombotic microangiopathy (1.2).

limitation of use

soliris is not indicated for the treatment of patients with shiga toxin e. coli related hemolytic uremic syndrome (stec-hus).

a c the treatment of adult patients with generalized myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody positive (1.3).

dosage and administration

for intravenous infusion only

pnh dosage regimen: (2.2)

ahus dosage regimen: (2.3)

gmg dosage regimen (2.4)

dosage forms and strengths

injection: 300a mg/30a ml (10a mg/ml) in single-dose vial (3).

contraindications

soliris is contraindicated in:

a c patients with unresolved serious neisseria meningitidis infection (4).

a c patients who are not currently vaccinated against neisseria meningitidis, unless the risks of delaying soliris treatment outweigh the risks of developing aa meningococcal infectiona (5.1).

warnings and precautions

a c discontinue soliris in patients who are being treated for serious meningococcal infections (5.4).

a c use caution when administering soliris to patients with any other systemic infection (5.2).

adverse reactions

the most frequently reported adverse reactions in the pnh randomized trial (a y10% overall and greater than placebo) are: headache, nasopharyngitis, back pain, and nausea (6.1).

the most frequently reported adverse reactions in ahus single arm prospective trials (a y20%) are: headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia (6.1).

the most frequently reported adverse reaction in the gmg placebo-controlled clinical trial (a y10%) is: musculoskeletal pain (6.1).

what is ipilimumab (yervoy)?

ipilimumab is a cancer medicine that is used alone or in combination with other medicines to treat certain types of cancer such as:

skin cancer (melanoma);

non-small cell lung cancer (nsclc);

pleural mesothelioma (cancer that affects the lining of the lungs and chest wall);

kidney cancer;

liver cancer; or

colorectal cancer that has certain specific dna mutations.

ipilimumab is often given when the cancer has spread to other parts of the body, or cannot be surgically removed, or has come back after prior treatment.

ipilimumab is given for nsclc only if your tumor tests positive for pd-l1 and does not have an abnormal egfr or alk (a specific genetic marker).

ipilimumab may also be used for purposes not listed in this medication guide.

what are the possible side effects of ipilimumab (yervoy)?

get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

some side effects may occur during the injection. tell your caregiver if you feel dizzy, light-headed, short of breath, itchy, tingly, chilled, or feverish.

serious and sometimes fatal reactions may occur during treatment with ipilimumab or months after stopping. call your doctor right away if you have symptoms such as:

severe or ongoing diarrhea, severe stomach pain, bloody or tarry stools;

fever, swollen glands, body aches;

new or worsening skin rash, itching, or blistering;

chest pain, irregular heartbeats;

severe muscle weakness, ongoing pain in your muscles or joints;

numbness or tingling in your hands or feet;

vision problems, eye pain or redness;

lung problemsnew or worsening cough, chest pain, feeling short of breath;

kidney problemslittle or no urination, swelling in your feet or ankles, blood in your urine;

liver problemsright-sided upper stomach pain, tiredness, bruising or bleeding, dark urine, yellowing of your skin or eyes;

signs of a hormonal disorderfrequent or unusual headaches, lack of energy, dizziness, fainting, mood or behavior changes, increased thirst or urination, feeling cold, weight gain, or weight loss; or

symptoms of brain swellingconfusion, headache, memory problems, hallucinations, neck stiffness, drowsiness, seizure (convulsions).